triple agonist glp 1 GLP-1 receptor agonist-based therapies and cardiovascular risk: a review of mechanisms in: Journal of Endocrinology Volume 263 Issue 1 (2024)

There's a new name in the GLP conversation — and it's worth paying attention to. Retatrutide is a triple-agonist therapy that targets GLP-1, GIP, and glucagon receptors simultaneously. In clinical trials, it

23.27

★★★★☆4.8 (126)

Treatment with retatrutide, an agonist to GLP-1, GIP, and glucagon receptors in one molecule, was associated with unprecedented drops in weight from people with or without type 2 diabetes in a pair

26.81

★★★★★4.9 (98)

The current significance and prospects for the use of dual receptor agonism GLP-1/Glucagon

22.63

★★★★★5.0 (157)

GLP-1-based therapies for type 2 diabetes: from single, dual and triple agonists to endogenous GLP-1 production and L-cell differentiation | Diabetology & Metabolic Syndrome

26.72

★★★★★4.7 (84)

Retatrutide: The GLP-1/GIP/Glucagon Triple-Agonist Guide to Weight Loss, Appetite Control & Metabolic Reset: Strong, Mike: 9798268084771: Amazon.com: Books

28.46

★★★★★4.9 (203)

Emerging Trends in the Development of GLP-1 Receptor Agonists

28.98

★★★★★5.0 (176)

Retatrutide. The triple agonist that's redefining metabolic research. 🧬 One compound. Three receptors. Unprecedented research potential. GIP → insulin response research GLP-1 → appetite suppression studies Glucagon → energy expenditure modulation No

27.94

★★★★★4.8 (132)